FILSPARI (sparsentan) – Acute Kidney Injury

FILSPARI (sparsentan) – Impact on Pregnancy, Lactation, and Fertility

FILSPARI (sparsentan) – DUPLEX (Phase 3 Study): Study Design & Topline Results

FILSPARI (sparsentan) Dual Receptor Antagonism in Renal Pathophysiology and Reduction of Proteinuria

FILSPARI (sparsentan) – Decreases in Hemoglobin

FILSPARI (sparsentan) – Mechanism of Action and Pharmacology

FILSPARI (sparsentan): Elevated Liver Transaminases and Hepatic Safety Results

FILSPARI (sparsentan) – Concomitant Medications Included in Clinical Trials

FILSPARI (sparsentan) – Changes in Blood Pressure and Hypotensive Events

FILSPARI (sparsentan) – Safety and Efficacy in Focal Segmental Glomerulosclerosis (FSGS)

FILSPARI (sparsentan) – Use with Diuretics in IgA Nephropathy and FSGS

FILSPARI (sparsentan) – Transitioning from ACEi/ARB Treatment to Sparsentan in Clinical Trials

FILSPARI (sparsentan) – Dosing and Administration in Clinical Trials